Erythrocytes are altered in pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Erythrocytes are altered in pulmonary arterial hypertension

Published:2022-05-20 Issue:6 Volume:59 Page:2200506
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Jutant Etienne-Marie^ORCID,Tu Ly,Thuillet Raphaël,Picard Véronique,Guignabert Christophe^ORCID,Parent Florence,Sitbon Olivier^ORCID,Humbert Marc^ORCID,Savale Laurent^ORCID,Huertas Alice^ORCID

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference15 articles.

1. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure

2. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease

3. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension

4. Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.

5. Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension